Chinese Drug Ingredient Supplier Draws 61 Complaints of Flaws
- FDA sent warning letter to Zhejiang Hisun Pharmaceutical
- Hisun deleted quality tests, some products banned from U.S.
This article is for subscribers only.
A Chinese pharmaceutical supplier now banned from sending some products to the U.S. was the target of a “significant number” of drugmaker complaints about the potency and purity of its ingredients, government records show.
Drug manufacturers lodged at least 61 complaints against Zhejiang Hisun Pharmaceutical Co., a maker of key components for drugs ranging from cholesterol to cancer treatments, between 2012 and 2014, according to a U.S. Food and Drug Administration warning letter sent to the company Dec. 31.